Program
GFS202A
A development code. Also written as “GFS202A injection”.
Its studies are mostly in Cachexia, led by Genfleet Therapeutics (Shanghai).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) | 11 open or running | phase 1since Mar 14, 2025 | Mar 14, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2025First study: phase 1 study in CachexiaFirst studyNCT06898255 · 36 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06898255Cachexia · China | 1 | Recruiting | Jun 8, 2026 | 36 |
How it is read
Names in the registry
- “GFS202A injection”, 1 entry
Codes read as this program: GFS202A.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.